This document discusses cancer and potential complementary and adjuvant treatments. It summarizes the characteristics and current treatment approaches for cancer. It then discusses various medicinal mushrooms and compounds that show promise as complementary agents, including polysaccharides from Coriolus versicolor and Phellinus linteus, and the compound Antroquinonol isolated from Antrodia camphorata. Antroquinonol in particular has shown safety and efficacy against various cancer types in both in vitro and in vivo studies. The document concludes by discussing how these natural compounds can be applied at different stages of cancer prevention and treatment.
Dose selection trial of metronomic oral vinorelbine monotherapy in patients w...Enrique Moreno Gonzalez
Metronomic chemotherapy is considered an anti-angiogenic therapy that involves chronic administration of low-dose chemotherapy at regular short intervals. We investigated the optimal metronomic dose of oral vinorelbine when given as monotherapy in patients with metastatic cancer.
Metronomic Chemotherapy Vs Best Supportive Care in Progressive Pediatric Tumors.Pranav Sopory
Journaal Club discussing the Randomised Clinical Trial (RCT) of metronomic chemotherapy in extra cranial, non-hematopoietic solid malignancies in paediatric population (aged 5-18 years). Courtesy Dr Atul Batra, Asst. Prof. Medical Oncology, IRCH, AIIMS.
Dose selection trial of metronomic oral vinorelbine monotherapy in patients w...Enrique Moreno Gonzalez
Metronomic chemotherapy is considered an anti-angiogenic therapy that involves chronic administration of low-dose chemotherapy at regular short intervals. We investigated the optimal metronomic dose of oral vinorelbine when given as monotherapy in patients with metastatic cancer.
Metronomic Chemotherapy Vs Best Supportive Care in Progressive Pediatric Tumors.Pranav Sopory
Journaal Club discussing the Randomised Clinical Trial (RCT) of metronomic chemotherapy in extra cranial, non-hematopoietic solid malignancies in paediatric population (aged 5-18 years). Courtesy Dr Atul Batra, Asst. Prof. Medical Oncology, IRCH, AIIMS.
Cancer chemoprevention with dietary phytochemicalsdegarden
Young-Joon Surh
Chemoprevention refers to the use of agents to inhibit, reverse or retard tumorigenesis.
Numerous phytochemicals derived from edible plants have been reported to interfere with a
specific stage of the carcinogenic process. Many mechanisms have been shown to account
for the anticarcinogenic actions of dietary constituents, but attention has recently been
focused on intracellular-signalling cascades as common molecular targets for various
chemopreventive phytochemicals.
Melinda Yushak, MD, MPH, a medical oncologist at Winship Cancer Institute of Emory University presents How to Approach Systemic Treatment for Metastatic Disease (Ocular Melanoma) at the 2016 CURE OM Patient & Caregiver Symposium.
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...Emad Shash
Tumor conferences are multidisciplinary meetings at which the
management of cancer patients is discussed. They have been
an integral part of oncology services and are regarded
as an essential component of quality control and continuing
medical education. There are data to suggest that the tumor conference enhances patient care. Many studies of effectiveness have been conducted. Reported benefits include improved patient management and treatment. In this presentation, I'll try to assess the role of the multidisciplinary tumor conference in patient management in gynecologic oncology services.
Dr. Manuel Hidalgo - Simposio Internacional ' Terapias oncológicas avanzadas'Fundación Ramón Areces
Los días 15 y 16 de octubre de 2014, la Fundación Ramón Areces y la Real Academia Nacional de Farmacia, en colaboración con la Fundación de la Innovación Bankinter, reunieron en Madrid a algunos de los mayores expertos mundiales en nuevas terapias contra el cáncer. El Simposio Internacional, coordinado por la profesora y académica María José Alonso, analizó el momento actual de la lucha contra esta enfermedad. También fue un punto de encuentro para científicos de los más innovadores institutos de investigación en oncología, quienes debatieron sobre tres grandes temas: la Medicina Personalizada contra el cáncer, los nanomedicamentos en la terapia del cáncer y las terapias basadas en la inmunomodulación.
The dream of any physician and consequently every patient is to receive the right treatment in the right time with cost effectiveness. To achieve this goal, the 3 pillars: evidence based medicine, clinical research innovation & resources utilization should be integrated efficiently.
In this presentation, I'll try to comprehensively review the following:
1- How are we used to perform clinical trials in Oncology?
2- Does it fits in today’s needs?
3- Integration of biology knowledge in shaping drug development
4- New Clinical trial designs “Can they offer solution for accelerating drug development?”
5- The supporting infrastructure role in clinical trial execution
Dr. Patrick Hwu presents the latest information on immunotherapies for melanoma at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Long Term Effects of Using Medicinal Mushroom Preparations in Human Colorecta...Neven Jakopovic
52 patients with bowel cancer and 89 with breast cancer used medicinal mushroom extracts from Myko San company with standard oncological treatments. In this cohort study, lasting from 2005-2010, we analysed the long term effects of using medicinal mushroom products in cancer patients.
While medicinal mushrooms are not 'magic bullets', this study provides unquestionable evidence of the benefits of their use as supportive therapy in cancer patients, leading to significantly improved outcomes.
This work was presented by Neven Jakopovic at the 6th International Medicinal Mushroom Conference in Zagreb, Croatia, in 2011.
Treatment of Ovarian Cancer First Line Chemotherapy or Targeted Therapy for R...ijtsrd
Ovarian cancer is the seventh most common gynecological cancer worldwide, ovarian cancer is the eighth leading cause of cancer death in women. In recent years, the number of ovarian cancer cases has been increasing in Japan, more than 9,000 women are diagnosed with ovarian cancer each year. The 5 year survival rate is 58 , the lowest among gynecological cancers, 4,758 ovarian cancer deaths in 2012. That is, it is reported that about one in two ovarian cancer patients has died. Because it is difficult to cure recurrent ovarian cancer, treatment is used to prolong life and improve quality of life. Because PARP inhibitors are oral targeted drugs that specifically act on cancer cells, they are expected to reduce the risk of disease progression and death while maintaining a good safety profile. In this way, the development of oral preparations has made it possible to avoid the burden on patients such as pain caused by conventional injections and the time constraints required for infusion. In this review, we discuss new treatments for ovarian cancer. Takuma Hayashi | Kaoru Abiko | Ken Yamaguchi | Junzo Hamanishi | Masaki Mandan | Ikuo Konishi "Treatment of Ovarian Cancer: First-Line Chemotherapy or Targeted Therapy for Recurrent Cases" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-3 , April 2020, URL: https://www.ijtsrd.com/papers/ijtsrd30470.pdf Paper Url :https://www.ijtsrd.com/medicine/other/30470/treatment-of-ovarian-cancer-firstline-chemotherapy-or-targeted-therapy-for-recurrent-cases/takuma-hayashi
Identifying candidate targets for Cancer Therapy with Integrated Text Mining ...Ann-Marie Roche
In this 60 minute webinar, Philip L. Lorenzi Ph.D. talked to us about autophagy, a programmed process in which cell contents are delivered to lysosomes for degradation and which appears to have both tumor-suppressive and tumor-promoting functions. Phillip and his colleagues have compiled a comprehensive, curated inventory of autophagy modulators by integrating information from published siRNA screens, multiple pathway analysis algorithms, and extensive text-mining of the literature and he will provide extensive analysis of their sources of information and their complex relationships with each other.
Cancer chemoprevention with dietary phytochemicalsdegarden
Young-Joon Surh
Chemoprevention refers to the use of agents to inhibit, reverse or retard tumorigenesis.
Numerous phytochemicals derived from edible plants have been reported to interfere with a
specific stage of the carcinogenic process. Many mechanisms have been shown to account
for the anticarcinogenic actions of dietary constituents, but attention has recently been
focused on intracellular-signalling cascades as common molecular targets for various
chemopreventive phytochemicals.
Melinda Yushak, MD, MPH, a medical oncologist at Winship Cancer Institute of Emory University presents How to Approach Systemic Treatment for Metastatic Disease (Ocular Melanoma) at the 2016 CURE OM Patient & Caregiver Symposium.
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...Emad Shash
Tumor conferences are multidisciplinary meetings at which the
management of cancer patients is discussed. They have been
an integral part of oncology services and are regarded
as an essential component of quality control and continuing
medical education. There are data to suggest that the tumor conference enhances patient care. Many studies of effectiveness have been conducted. Reported benefits include improved patient management and treatment. In this presentation, I'll try to assess the role of the multidisciplinary tumor conference in patient management in gynecologic oncology services.
Dr. Manuel Hidalgo - Simposio Internacional ' Terapias oncológicas avanzadas'Fundación Ramón Areces
Los días 15 y 16 de octubre de 2014, la Fundación Ramón Areces y la Real Academia Nacional de Farmacia, en colaboración con la Fundación de la Innovación Bankinter, reunieron en Madrid a algunos de los mayores expertos mundiales en nuevas terapias contra el cáncer. El Simposio Internacional, coordinado por la profesora y académica María José Alonso, analizó el momento actual de la lucha contra esta enfermedad. También fue un punto de encuentro para científicos de los más innovadores institutos de investigación en oncología, quienes debatieron sobre tres grandes temas: la Medicina Personalizada contra el cáncer, los nanomedicamentos en la terapia del cáncer y las terapias basadas en la inmunomodulación.
The dream of any physician and consequently every patient is to receive the right treatment in the right time with cost effectiveness. To achieve this goal, the 3 pillars: evidence based medicine, clinical research innovation & resources utilization should be integrated efficiently.
In this presentation, I'll try to comprehensively review the following:
1- How are we used to perform clinical trials in Oncology?
2- Does it fits in today’s needs?
3- Integration of biology knowledge in shaping drug development
4- New Clinical trial designs “Can they offer solution for accelerating drug development?”
5- The supporting infrastructure role in clinical trial execution
Dr. Patrick Hwu presents the latest information on immunotherapies for melanoma at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Long Term Effects of Using Medicinal Mushroom Preparations in Human Colorecta...Neven Jakopovic
52 patients with bowel cancer and 89 with breast cancer used medicinal mushroom extracts from Myko San company with standard oncological treatments. In this cohort study, lasting from 2005-2010, we analysed the long term effects of using medicinal mushroom products in cancer patients.
While medicinal mushrooms are not 'magic bullets', this study provides unquestionable evidence of the benefits of their use as supportive therapy in cancer patients, leading to significantly improved outcomes.
This work was presented by Neven Jakopovic at the 6th International Medicinal Mushroom Conference in Zagreb, Croatia, in 2011.
Treatment of Ovarian Cancer First Line Chemotherapy or Targeted Therapy for R...ijtsrd
Ovarian cancer is the seventh most common gynecological cancer worldwide, ovarian cancer is the eighth leading cause of cancer death in women. In recent years, the number of ovarian cancer cases has been increasing in Japan, more than 9,000 women are diagnosed with ovarian cancer each year. The 5 year survival rate is 58 , the lowest among gynecological cancers, 4,758 ovarian cancer deaths in 2012. That is, it is reported that about one in two ovarian cancer patients has died. Because it is difficult to cure recurrent ovarian cancer, treatment is used to prolong life and improve quality of life. Because PARP inhibitors are oral targeted drugs that specifically act on cancer cells, they are expected to reduce the risk of disease progression and death while maintaining a good safety profile. In this way, the development of oral preparations has made it possible to avoid the burden on patients such as pain caused by conventional injections and the time constraints required for infusion. In this review, we discuss new treatments for ovarian cancer. Takuma Hayashi | Kaoru Abiko | Ken Yamaguchi | Junzo Hamanishi | Masaki Mandan | Ikuo Konishi "Treatment of Ovarian Cancer: First-Line Chemotherapy or Targeted Therapy for Recurrent Cases" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-3 , April 2020, URL: https://www.ijtsrd.com/papers/ijtsrd30470.pdf Paper Url :https://www.ijtsrd.com/medicine/other/30470/treatment-of-ovarian-cancer-firstline-chemotherapy-or-targeted-therapy-for-recurrent-cases/takuma-hayashi
Identifying candidate targets for Cancer Therapy with Integrated Text Mining ...Ann-Marie Roche
In this 60 minute webinar, Philip L. Lorenzi Ph.D. talked to us about autophagy, a programmed process in which cell contents are delivered to lysosomes for degradation and which appears to have both tumor-suppressive and tumor-promoting functions. Phillip and his colleagues have compiled a comprehensive, curated inventory of autophagy modulators by integrating information from published siRNA screens, multiple pathway analysis algorithms, and extensive text-mining of the literature and he will provide extensive analysis of their sources of information and their complex relationships with each other.
Final presentation for BIOL405, NSC, Spring 2014. Presented by Kevin Hugins and Duy-Khiem Chanh Pham. This presentation addressed the use of Chimeric Antigen Receptors for gene therapy for cancer. Gene therapy was first conceptualized to alter debilitating fates of genetic diseases. Gene therapy technology can help introduce new functional DNA to replace mutated genes. The idea first arose in 1972 when Friedmann and Roblin authored a paper, “Gene therapy for human genetic disease?”, demonstrating that exogenous DNA can be taken up by mammalian cells (1). They proposed that the same procedure could be done on humans to correct genetic defects by introducing therapeutic DNA. Currently, genetic modification of T lymphocytes has been the major area of research for treating malignant tumors. This technique seeks to create chimeric antigen receptor (CAR) in T cells by genetically modifying them in vitro and reintroduce them back into blood circulation. The T cells are unique to every patient and the chimeric antigen receptors are unique to the tumor that it is targeting.
This presentation is part of MIU CE Pharmacy Program and is designed primarily for pharmacists with the following learning objectives:
1- Explain the mechanisms of action behind immune response to cancer and the application of immunotherapy in cancer treatment
2- Distinguish new and emerging immunotherapy classes and individual agents efficacy, safety to therapy in cancer treatment
3-Strategies to counsel and assist patients to overcome barriers to therapy, including Treatment side effects to improve adherence to therapy
BREAST CANCER DRUG DISCOVERY & RESEARCH FROM VARIOUS WELL KNOWN ETHNOMEDICINAL PLANTS. ESTABLISHED PHYTOMOLECULES WITH CHEMOPREVENTIVE, ANTICANCER ACTIVITIES WITH MINIMAL TOXICITY.
Phytochemical and anti proliferative activity of Nigella sativa (Kalonji)Saptarshi Samajdar
Highly potent plant having very useful pharmacological effect especially in anticancer studies and various other diseases. It is even called Panacea because it can cure all diseases except death. Various religious books mention its existence as potent herbal drug.
Similar to Premier on Medicinal Fungus as effective Adjuvant & Complementary Agents for Cancer Therapy (20)
Phytochemical and anti proliferative activity of Nigella sativa (Kalonji)
Premier on Medicinal Fungus as effective Adjuvant & Complementary Agents for Cancer Therapy
1. Mr. LEE Chee Cheow (M.Sc.) Chief Scientific Officer,
International Advanced Bio-Pharmaceutical Industries Pte Ltd.
Promoting the Nutriceutical Science of Preventive Self-care
Effective
Adjuvant & Complementary Agents
for
Cancer Therapy
Medicinal Fungus
2. Cancer Etiolopathology
Characteristics of Cancer Cells
The problem:
Cancer cells divide rapidly
(cell cycle is accelerated)
They are “immortal”
Cell-cell communication is altered
Uncontrolled proliferation
Invasiveness
Ability to metastasise
Current major approaches to
Therapy of cancers
Six Established Rx Modalities:
1. Surgery
2. Radiotherapy
3. Chemotherapy
4. Endocrine therapy
5. Immunotherapy
6. Targeted therapy
3. Current Cancer Treatment
• Rarely is a single agent effective
• Rather, multiple agents and treatment
modalities are used
4. SYNERGY (Chemo + TCM) Cancer Treatment
is more effective than Chemo or TCM alone
Study Centers
Treatment
Group
Patient
size
Median Survival
Time (months)
Lin xx
(8 hospitals)
Synergy
Chemo
TCM
199
215
173
12.03
8.46
10.92
Chou xx
(6 hospitals)
Synergy
Chemo
TCM
103
92
99
11.8
7.9
9.7
Liu & Fan
(10 Hospitals)
Synergy
Chemo
TCM
137
146
74
19.4
14.53
14.02
Results of multi-center,
randomized, parallel,
controlled, prospective
study methods to
evaluate the
effectiveness and
safeness of using
Synergy Medicine
treatment in
advanced NSCLC
patients.
Extract from clinical presentation at SGH on “Demonstration of Synergy Medicine treatment research in advanced non-small
cell lung cancer” by Prof. Liu Jia Xiang & Prof. Fan Zhong Ze , Shanghai University of TCM.
5. Chemotherapy drugs
• They are Anti- proliferative
– i.e. they damage DNA and so initiate apoptosis (programmed cell dead).
• They also affect rapidly dividing normal cells
– e.g. bone marrow, hair follicles, sperm forming cells.
TISSUE TYPE UNDESIRED EFFECTS
Bone marrow Low white blood cell > infection risk
Immunosuppression
Low red blood cell > Anemia
GI tract Oral or intestinal ulceration; Diarrhea
Hair follicles Alopecia (Hair loss)
Gonads
Menstrual irregularities, including premature
menarche; impaired spermatogenesis
Wounds Impaired healing
Fetus Teratogenesis (especially during first trimester)
Adverse Drug Reactions (side effects)
of Anti-neoplastic (Chemo) Drugs
6. Adjuvant & Complementary
Cancer Treatments
Goals:
Helps potentiate the efficacies of existing anti-cancer chemotherapeutical drugs.
Helps eradicate microscopic cancer after surgery
Helps alleviate symptoms and prevents the decline in immunity
Avoidance of life-threatening toxicity
Increased survival and improved quality of life
7. Medicinal mushrooms
Many Pharmaceuticals are derived from
the Fungus Kingdom:
• Penicillin (antibiotic)
• Ciclosporin (immunosuppressant)
• Griseofulvin (antifungal)
• Statins (cholesterol lowering)
• Mushrooms are prebiotic
• They have immune system enhancement
properties
• They are anti tumour agents
11. Polysaccharide-peptide (PSP) of
Coriolus versicolor
Pharmacological Actions:
control the growth of tumour cells
• lung cancer
• stomach cancer
• lymphoma
• leukemia
• sarcoma-180
Clinical applications:
• Adjuvant to chemo & radiation therapy
• Significantly improved immunity of immune
suppressed patients during treatment, reduce
toxicity caused by chemotherapy.
• Relieve symptoms of: fatigue, nausea, vomiting,
dry mouth, anxiety, cold sweating.
• Improve appetite, relieve pain, improve sleep
quality, improve overall quality of life of patients
during treatment.
• PSP activates monocytes in resting human peripheral blood mononuclear cells: Immunomodulatory implications for
cancer treatment; Food Chemistry, Volume 138, Issue 4, 15 June 2013, Pages 2201-2209
• A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus
versicolor Review Article; General Pharmacology: The Vascular System, Volume 30, Issue 1, January 1998, Pages 1-4
12. Phellinus linteus
• Medicinal mushroom Phellinus linteus
(Berk. et Curt.) has been used in traditional
oriental medicine in Japan, China & Korea.
• Study in Japan demonstrated that PL has
strongest anti tumor effects compared to
other mushrooms.
Anti tumor Biological activities
• ANGIOGENESIS
• APOPTOSIS
• CHEMOPREVENTION
• Anti INVASIVE
• Anti PROLIFERATION
Other pharmacological effects:
• immunomodulatory
• anti-inflammatory
• anti-allergic
• anti-oxidant
Anticancer Effect of Phellinus linteus ; Potential Clinical Application in Treating
Pancreatic Ductal Adenocarcinoma; Kang et al., J Carcinogene Mutagene 2013, S9
13. Phellinus linteus
Medicinal mushroom Phellinus linteus as an alternative cancer therapy (Review); Experimental and therapeutic medicine 1:
407-411, 2010
14. Antrodia Camphorata: A Rare Fungus
World’s most
valuable medicinal
fungus compared:
Bio-Active Ingredients Ganoderma Lucidium Antrodia Camphorata
Bio Active Triterpenes 20-50 types >200 types
Triterpenes concentration 1 – 3 % 10-45 %
AC is highly priced for its effectiveness in treating
the following ailments over centuries in Taiwan:
• Anti-cancer
• Improve liver functions
• Anti Fatigue
• Anti-inflammation
• Anti-hepatitis infection
• Improve immunity
• Anti-allergenic
15. Product Information :
IMMUNO CPX: A cancer therapeutic formulation
developed by 2 Taiwan medical University in
collaboration with Japan genetic research
institute, base on immunotherapy approach.
Indication:
• Used as a immunotherapy adjuvant to cancer treatment along
with surgery, chemotherapy and radiation therapy.
• Helps to potentiate the efficacies of existing anti-cancer
chemotherapeutical drugs.
• Helps alleviate symptoms and prevents the decline in immunity.
INGREDIENT:
• Antrodia camphorata mycelium
• Phellinus linteus mycelium
• Coriolus versicolor polysaccharide
• Extractum curcumae longae
Immunotherapy:
A New Anticancer Approach
Also called biological therapy, immunotherapy aims to
boost a person's immune system to fight disease.
Clinical application:
16. KEY FEATURES:
High Safety
No Resistant for Liver Cancer and others
cancer therapies from non-option patient
experience
• USFDA Patent 7342137 Mar.11,2008
• USFDA Patent 7385088 Jun.10,2008
• USFDA Patent 7411003 Aug.12,2008
• USFDA Patent 7456225 Nov.25,2008
• USFDA Patent 7501454 Mar.10,2009
• USFDA Patent 7468392 Dec.23.2008
Antroquinonol®
High safety
High performance
Anti cancer compound
Based on Human Cancer Cell,
Antroquinonol® can Assist the Treatment of Multiple Therapies in Solid Tumor.
New Anti Cancer Compound
Isolated from Antrodia Camphorata
OH
O
O
O 1
2
3
4
5
6
22
7
8
9
21
10
11
12
13
20
14
15
16
17
18
19
23
24
Safety:
Orally active with high safety profile:
1. MTD in Rat : >100 mg/kg/day;
2. No System toxicity in Rat & Dog: 100 mg/kg/day
3. LD50>1,000mg/kg/day in Dogs
4. NOEL (No Observed Effect Level) Teratology : >80 mg/kg
5. NOAEL (No Observed Adverse Effect Level) in Rat & Dog = 30 mg/kg/day
17. Wide spectrum anti solid tumor effects
BROAD SPECTRUM ANTI CANCER PROPERTIES:
Antroquinonol inhibited the growth of various types
of cancer cells in culture
19. Antroquinonol inhibits NSCLC proliferation by altering PI3K/mTOR proteins and miRNA expression profiles; Mutation Research 707 (2011) 42–52
Lung Cancer cells: Anti proliferative effect
20. Liver Cancer cells: Anti proliferative effect
Antroquinonol displays anticancer
potential against human
hepatocellular carcinoma cells: A
crucial role of AMPK and mTOR
pathways; Biochem Pharmacol.
2010 Jan 15;79(2):162-71.
PMID:19723512
21. Source:
The Augmented Anti-Tumor
Effects of Antrodia
camphorata Co-Fermented
with Chinese Medicinal Herb
in Human Hepatoma Cells;
The American Journal of
Chinese Medicine, Vol. 37,
No. 4, 771–783;
Adjuvant with cisplatin & paclitaxel
26
Anti Liver Cancer Properties
HepG2 Liver Cancer cells
22. Source:
The adjuvant effects of Antrodia Camphorata extracts
combined with anti-tumor agents on multidrug resistant
human hepatoma cells. Journal of Ethnopharmacology
118 (2008) 387–395
Anti Liver Cancer Properties
Adjuvant with Chemotherapy
Multidrug resistant
(A)C3A & (B)PLC/PRF/5
hepatoma cells
23. • Under go targeted chemo therapy
• Nesavar (Sorafenib) 30 days
Clinical Case Report
Patient (Diabetic with Kidney Dialysis):
• Suffered from primary Liver cancer.
• 4 months after Liver resection,
• Diagnose with late stage metastatic Lung cancer.
Diagnose with late stage metastatic Lung cancer.
CT scan show continue presence of Tumor
• Change chemo regime
• Take Antroquinonol 400mg / day x 24 days
CT scan show complete absence of Tumors
24. Antroquinonol®
isolated from AC
Functions of Antroquinonol in adjuvant and combination chemotherapy:
• Increased cancer cell kill :
• Administration of drugs with different mechanisms of action.
• Suppression of drug resistance
• Helps reduced injury to normal cells :
• It provide Hepatoprotection against drug toxic side effects
• Support Immunity against infections
Clinical application:
Antroquinonol is currently use as adjuvant/combination agent to existing
chemotherapy or as primary agent for non options cancer patients.
December 2013:
Antroquinonol is approved by US FDA enter into phase 2 clinical trial (NCT01134016)
25. Common Symptoms of
Cancer Palliative Care Outpatients
• Pain 82%
• Easy fatigue 67%
• Weakness 64%
• Anorexia 64%
• Weight loss 60%
• Lack of energy 59%
• Dry mouth 55%
• Constipation 51%
• Dyspnea 51%
• Easy satiety 50%
• Sleep problems 47%
• Depression 40%
Adapted from Donnelly et al.
26. Cancer Type Range
Early disease 48% (38%-100%)
Advanced disease 74% (53%-100%)
Pancreas 72%-85%
Esophagus 71%-77%
Head & neck 67%-91%
Genitourinary 58%-90%
Prostate 56%-94%
Breast 40%-89%
Prevalence of Cancer Pain
Cancer Pain: Assessment and
Management. 2003:38-50:
27. Common Cancer Pain by Pathophysiology
• Bone metastases
• Skin lesions
• Malignant bowel obstruction
• Chemotherapy-induced peripheral neuropathy
Causes of Cancer Pain (Etiology) Prevalence
Due to cancer 85%-93%
Due to diagnosis & treatment 17%-21%
Unrelated to diagnosis & treatment 2%-9%
Pain;1995:63;65-76
Pain;1999:82:263-274
Causes of Cancer Pain
30. Effective chemopreventive agents:
Multi-pronged anti cancer approach
Wide spectrum cancer (type) targets
Cancer Chemoprevention
Anti-cancer
Anti cell promotion
Anti cell proliferation
Activate cell death
Anti-toxin
Detoxification,
strengthen liver functions
Anti-infection
Strengthen immune systems
Anti-oxidation
Major categories of
chemopreventive agents
32. Centre for Adjuvant & Complementary Medicine
Company focus on offering Breakthrough Bio-Medical Product Solutions in
major areas of Aging Health Concerns that helps in the Prevention of Chronic
Illnesses of Modern Society, Extending and Enhancing the Quality of Life.
Company sub specialized in providing Pharmacological Therapy product
solutions for:
Chronic disease management
Critical illness recovery
Complimentary chemotherapy
High risk chemoprevention
INTERNATIONAL ADVANCED BIO-PHARMACEUTICAL INDUSTRIES PTE LTD
8 Boon Lay Way, #08-03 TradeHub 21, Singapore 609964
Tel: +65-68738693 Fax: +65-68738694 URL: www.iabpi.com
李咨潮 硕士 Mr LEE Chee Cheow (M.Sc. TCM Dip.)
科学主任
首席咨询顾问
Chief Scientific Officer
Principal Consultant, IABPI
Author:
Chief Scientist, CAM Pharmacologist & Nutriceutical Consultant
Areas of research interest includes:
Naturopathic & Integrated Medicine
Chemopreventive Therapy
Transdermal Drug Delivery system.